Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of 6% hydroxyethyl starch versus electrolyte solution in trauma patients
2016-002176-27Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hetastarch in hypovolemia and Physical trauma (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Composite primary endpoint: 90-day mortality and 90-day renal failure. Started Aug 2016; status: completed.
02
Drugs
hetastarch
03
Conditions
hypovolemiaPhysical trauma
Beyond the preview
Go deeper on 2016-002176-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002176-27.